New Lung Cancer Drug Shows 78% Response Rate in Advanced Cases
Pralsetinib demonstrates remarkable efficacy against rare RET fusion lung cancers with manageable side effects.
Summary
A breakthrough cancer drug called pralsetinib showed impressive results against a rare but aggressive form of lung cancer. In a major clinical trial, 78% of previously untreated patients and 63% of those who had failed prior chemotherapy experienced tumor shrinkage. The drug targets a specific genetic mutation called RET fusion, found in 1-2% of lung cancers. Patients lived a median of 44 months, with some surviving over 50 months. While side effects included anemia and high blood pressure, they were generally manageable. This represents a significant advance for patients with limited treatment options.
Detailed Summary
This landmark study demonstrates how precision medicine is revolutionizing cancer treatment, offering hope for patients with previously difficult-to-treat genetic subtypes of lung cancer that could inform broader therapeutic approaches.
Researchers conducted the ARROW trial, testing pralsetinib in 281 patients with advanced non-small cell lung cancer harboring RET fusions. This oral medication specifically targets the abnormal RET protein driving tumor growth in these rare cancers.
The results were remarkable: 78% of treatment-naive patients experienced tumor shrinkage, while 63% of those previously treated with chemotherapy responded. Median overall survival reached 44.3 months, with treatment-naive patients living 50.1 months on average. The drug was taken once daily at 400mg, with a median treatment duration of 15 months.
Side effects were manageable, with the most common severe reactions being anemia (21%), high blood pressure (15%), and low white blood cell counts (13%). Only three treatment-related deaths occurred among 281 patients, indicating a favorable safety profile.
These findings represent a paradigm shift toward personalized cancer therapy based on genetic profiling rather than tumor location alone. The success of pralsetinib validates the approach of targeting specific molecular drivers, potentially extending both lifespan and quality of life for cancer patients. However, this treatment applies only to the small subset of lung cancer patients with RET fusions, highlighting the importance of comprehensive genetic testing for optimal treatment selection.
Key Findings
- Pralsetinib achieved 78% response rate in untreated RET fusion lung cancer patients
- Median overall survival reached 44.3 months across all patients in the study
- Treatment-naive patients lived median 50.1 months with manageable side effects
- Only 3 treatment-related deaths occurred among 281 patients treated
- Drug targets rare RET fusion mutations found in 1-2% of lung cancers
Methodology
Phase I/II open-label study of 281 patients with RET fusion-positive non-small cell lung cancer receiving pralsetinib 400mg daily. Median treatment duration was 15.0 months with data lock in May 2024. Primary endpoints were overall response rate and safety.
Study Limitations
Study applies only to 1-2% of lung cancer patients with specific RET fusions. Open-label design without control group limits comparison to standard treatments. Long-term safety data beyond median 15-month treatment duration remains limited.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.